1 / 22

Hepatitis C & HIV in 2011

Hepatitis C & HIV in 2011. Vincent Soriano Infectious Diseases Department Hospital Carlos III, Madrid, Spain. HCV epidemiology. 2-3% of the world population. >40% undiagnosed Routes of infection: sporadic >50% Risk factors: transfusions <1990; IVDU

fathi
Download Presentation

Hepatitis C & HIV in 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis C & HIV in 2011 Vincent Soriano Infectious Diseases Department Hospital Carlos III, Madrid, Spain

  2. HCV epidemiology • 2-3% of the world population. • >40% undiagnosed • Routes of infection: sporadic >50% • Risk factors: transfusions <1990; IVDU • 30% of chronic carriers will develop cirrhosis • HCV is the primary reason for liver transplantation • HCV is the major cause of liver cancer • No vaccine • Only curable (eradication) chronic viral infection

  3. The most prevalent chronic viral infections in humans HBV HCV 400 200 35 7 million HIV

  4. Hep B, C, D • Drug-related toxicity Deaths in a cohort of 23,441 HIV patients on HAART HCV Weber et al. Liver-related deaths in persons infected with HIV: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.

  5. No HAART Progression of HCV-related liver fibrosis in HIV patients Uncontrolled HIV replication Low CD4 counts HAART Metabolicabnormalities Hepatotoxicity of meds HIV-neg years

  6. RCT with PegIFN + RBV in HCV/HIV pts APRICOT RIBAVIC No. with Peg+RBV 288 194 IDUs 62% 81% Cirrhotics 15% 40%(F3-F4) Genotypes 1-4 67% 69% Normal ALT levels 0 16% Mean CD4 count 520 525 On HAART 84% 82% EOT (ITT) 49% 36% SVR (ITT) 40% 27%

  7. Unique AEs in HCV/HIV-coinfected patients under pegIFN+RBV * All seen in cirrhotics. Overall, it affected 10% of cirrhotics; associated to ddI (+ RBV) ** 1 out of 5 patients treated with ddI *** Associated with ddI and cirrhosis (OR = 9)

  8. W12 W48 W72 W4 W24 G2/3 24 weeks therapy HCV-RNA neg G1/4 48 weeks therapy G2/3 HCV-RNA neg G1/4 72 weeks therapy > 2 log drop in HCV-RNA HCV-RNA pos Stop HCV-RNA pos < 2 log drop in HCV-RNA Stop Current algorithm for HCV therapy in HIV(peginterferon + ribavirin) Soriano et al. AIDS 2007; 21: 1073-89.

  9. Predictors of response to HCV therapy • HCV genotype • Baseline serum HCV-RNA • Liver fibrosis stage • RVR • EVR • IL28B polymorphisms

  10. Response to pegIFN+RBV IL28B polymorphisms & hepatitis C outcome IL28B gene Interferon 3 SNP: rs12979860 (CC, CT, TT) Spontaneous HCV clearance Chromosome 19 Ge et al. Nature 2009; 461: 399-401. Thomas et al. Nature 2009; 461: 798-802. Suppiah et al. Nature Gen 2009; 41: 1100-4. Tanaka et al. Nature Gen 2009; 41: 1105-9.

  11. p=0.684 SVR 86% p<0.0001 81% p=0.001 p=0.087 75% 67% 65% 38% 30% 25% CC CT/TT CC CT/TT CC CT/TT CC CT/TT 89 61 12 75 34 16 6 35 All HCV-1 HCV-3 HCV-4 164 95 51 18 AIDS 2010

  12. 11.9 HCV-RNA <600,000 IU/ml p<0.001 8.0 HCV genotype 3 p<0.001 3.7 rs12979860 CC genotype p=0.002 3.5 p=0.009 Liver fibrosis stage F0-F2 0 5 10 15 20 25 30 35 40 Odds ratio (95% confidence interval) IL28B polymorphisms in HIV-HCV coinfection Rallon et al. AIDS 2010

  13. Prometheusindex • HCV genotype • Fibrosis stage (KPa) • Serum HCV-RNA • IL28B SNPs http://ideasydesarrollo.com/fundacion/prometheusindex.php

  14. http://ideasydesarrollo.com/fundacion/prometheusindex.php

  15. A new era for hepatitis C – new diagnostic tools & new weapons

  16. Challenges using DAA in HIV-HCV coinfection • More elevated HCV load. More virologicalfailures? • Fasterselection of drugresistance? • Drug-druginteractions • Overlappingtoxicities – rash & anemia • Drugcompliancewithpolymedication • Additionalcost

  17. Study 110Telaprevir in HIV-HCV coinfectedpts PRT PR % HCV-RNA <10 IU/ml % HCV-RNA <10 IU/ml 75 75 71 70 71 68 64 57 17 14 12 12 12 5 0 0 37 22 7 6 14 8 16 8 37 22 7 6 14 8 16 8 total No ARV ATV/r EFV total No ARV ATV/r EFV Week 12 Week 4 Sulkowski et al. CROI 2011, LB146

  18. Implications of widespread use of DAA • Shift in HCV genotypes in the infected population, being other genos replacing geno 1. • Changes in HCV-infected populations, with accumulation in poor regions and/or communities within rich countries. • Growing number of patients with drug-resistant mutant viruses and potential for transmission.

  19. A shift in care providers for hep C infectologist hepatologist virus liver The HCV doctor

  20. HBV HCV HIV 8th International Coinfection Workshop Madrid, May 30 - June 1, 2012 Chairmen: Vicente Soriano & Mark Sulkowski www.virology-education.com

  21. Acknowledgments ClinicLaboratory Pablo Barreiro Norma Rallon Pablo Labarga Ana Treviño Luz Martin-Carbonero Carmen de Mendoza Eugenia Vispo Eva Poveda Jose Medrano Sonia Rodriguez-Novoa Jose V Fernandez Jose Miguel Benito Juan Gonzalez-Lahoz

More Related